Más información

Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Troughton RW et al. Lancet 2000;355(9210):1126-30.
Ir a sitio web

Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Talwar S et al. Eur Heart J 2000;21(18):1514-21.
Ir a sitio web

A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. Cheng V et al. J Am Coll Cardiol 2001;37(2):386-91.
Ir a sitio web

The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Mair J et al. Clin Chem Lab Med 2001;39(7):571-88.
Ir a sitio web

Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Remme WJ. Eur J Heart Fail 2002;4(1):11-22.
Ir a sitio web

B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Yoshimura M et al. Am J Med 2002;112(9):716-20.
Ir a sitio web

Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Latini R et al. Circulation 2002;106(19):2454-8.
Ir a sitio web

Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Sinha AM et al. Am J Cardiol. 2003;91(6):755-8.
Ir a sitio web

Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Fung JW et al. Am J Cardiol 2003;92(4):406-10.
Ir a sitio web

Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Mir TS et al. Pediatrics 2003;112(4):896-9.
Descargar pdf

Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Packer M. Circulation 2003;108(24):2950-3.
Ir a sitio web

Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Sliwa K et al. Circulation 2004;109(6):750-5.
Ir a sitio web

NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Hartmann F et al. Eur J Heart Fail 2004;6(3):343-50.
Ir a sitio web

NT-proBNP in heart failure: therapy decisions and monitoring. Richards M, Troughton RW. Eur J Heart Fail 2004;6(3):351-4.
Ir a sitio web

Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. Rademaker MT et al. Clin Sci (Lond) 2004;106(6):569-76.
Ir a sitio web

Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Molhoek SG et al. Heart 2004;90(1):97-8.
Ir a sitio web

Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Kyrzopoulos S. Int J Cardiol 2005;99(3):409-13.
Ir a sitio web

Improvement of serum NT-proBNP predicts improvement in cardiac function and favourable prognosis after cardiac resynchronization therapy for heart failure. Yu CM. J Card Fail 2005;11(5 Suppl):S42-6.
Ir a sitio web